Observational studyScientific reports2025
Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The gut-skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management.Frontiers in microbiology · 2026Review
- Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling.Frontiers in immunology · 2026Review
- Microbiota-Metabolite-Host Crosstalk Mediates the Impact of Dietary Energy Levels on Colonic Homeostasis in High-Altitude Ruminants.Animals : an open access journal from MDPI · 2025Article
- Immunoproteasome Inhibition Positively Impacts the Gut-Muscle Axis in Duchenne Muscular Dystrophy.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota has been associated with carcinogenesis and immune regulation. While there is evidence supporting its influence on immunotherapy response in melanoma, its impact on BRAF/MEK-targeted therapy remains unexplored. This study assessed gut microbiota composition and immune-associated genes in melanoma, to generate hypothesis on prognostic and predictive biomarkers for BRAF/MEK inhibitor therapy. This prospective, observational study analyzed fecal and blood samples from 26 patients diagnosed with BRAF-mutated metastatic melanoma. Samples were collected at baseline (T0) and at first radiological evaluation (T1). Patients were stratified by treatment response and toxicity. Partial responders had baseline enrichment of Lachnospiraceae, Coriobacteriaceae, and Adlercreutzia. Complete responders showed abundance of Prevotellaceae, Cerasicoccaceae and Lawsonia. Oscillospira was associated with moderate-to-severe toxicity. Gene expression analysis revealed upregulation of TAP1 y PSMB8 during treatment in responders, with persistent downregulation of LAG3, CD36, SLAMF7, NOD1, SLAMF6, CX3CR1 and ICAM2. Overall, baseline microbiota composition differed by response depth, with abundance of Lachnospiraceae, Coriobacteriaceae, and Adlercreutzia in partial responders and Prevotellaceae, Cerasicoccaceae, and Lawsonia in complete responders. A gene signature of immune-suppresive genes was persistently downregulated in responders. Our findings suggest that specific gut microbial taxa and immune-related gene expression patterns may be associated with differential responses to BRAF/MEK-targeted therapy in metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.